A product includes a nanoporous membrane having a plurality of carbon nanotubes and a fill material in interstitial spaces between the carbon nanotubes for limiting or preventing fluidic transfer between opposite sides of the nanoporous membrane except through interiors of the carbon nanotubes. The longitudinal axes of the carbon nanotubes are substantially parallel, an average inner diameter of the carbon nanotubes is about 20 nanometers or less, and both ends of at least some of the carbon nanotubes are open. Moreover, the fill material is impermeable or having an average porosity that is less than the average inner diameter of the carbon nanotubes.

Provided are methods using and making functionalized silicon membranes, such as, for example, functionalized silicon nanomembranes. The methods may combine one or more (e.g., two) surface modification processes (e.g., using a combination of aldehydes and silanes). Also described are fluidic devices containing functionalized membranes of the present disclosure and uses thereof. The fluidic devices of the present disclosure include one or more functionalized silicon membrane.

A system for performing a peritoneal dialysis therapy includes at least one dialysis fluid pump, and a logic implementer operable with the at least one dialysis fluid pump to perform a plurality of peritoneal dialysis cycles for a patient. The logic implementer transmits an amount of dialysis fluid provided during the plurality of peritoneal dialysis cycles. A server receives the amount of dialysis fluid provided during the plurality of peritoneal dialysis cycles and determines an amount of ultrafiltration (UF) removed from the patient based on the amount of dialysis fluid provided by the at least one dialysis fluid pump. The server also updates a UF trend using previous amounts of UF removed from the patient and the amount of UF removed from the patient during the most recent dialysis treatment and generates an alert if the UF trend changes by more than a preset percentage.

A blood processing system for collecting plasma reduced platelets and anticipating plasma return includes a venous access device, a blood component separation device, a first return line, a recirculation line, and a second return line. The venous access device draws whole blood from a subject and returns blood components to the subject using a first pump. The blood component separation device separates the drawn blood into a first blood component and a second blood component, and sends the first blood component to a first blood component bag. The first return line fluidly connects the venous-access device and the blood component separation device. The recirculation line connects the first blood component container and the separation device. The second return line fluidly connects the first blood component container and the first return line and is configured to return the first blood component within the first blood container to the subject.

The present invention relates to an injectable homogeneous aqueous solution of chitosan containing, in a physiologically acceptable medium, between 0.1 and 4.5% by weight of a chitosan having a degree of acetylation less than 20% and a weight average molecular mass of between 100,000 and 1,500,000 g/mol, said solution having a pH greater than or equal to 6.2, and advantageously between 6.2 and 7.2, said solution not containing any chitosan having a degree of acetylation greater than 20%, said solution being liquid and homogeneous at ambient temperature. The invention also relates to an aqueous solution such as previously described, characterised in that it can be prepared by a method comprising at least the following steps: dissolving the chitosan in water by adding acid, such as a weak acid, said weak acid being advantageously chosen from the group consisting of acetic acid, glycolic acid, lactic acid, glutamic acid, and the mixtures of same, and readjusting the pH by dialysis, preferably at ambient temperature, in order to obtain an aqueous solution having a pH greater than or equal to 6.2, advantageously between 6.2 and 7.2, and preferably between 6.25 and 7.1.

The present disclosure relates to a dialyzer comprising a bundle of semipermeable hollow fiber membranes which is suitable for blood purification, wherein the dialyzer has an increased ability to remove larger molecules while at the same time it is able to effectively remove small uremic toxins and efficiently retain albumin and larger proteins. The invention also relates to using said dialyzer in hemodialysis.

A means capable of simply and efficiently concentrating a cell suspension. A concentrator has a culture vessel having a first port and a second port, a server bag having a port, a case having a hollow fiber bundle in the internal space, a filtering device having an inlet port, a first outlet port, and a second outlet port, a collection vessel having a port, a liquid supply circuit connected to the first port, the inlet port, and the server bag's port so that flow passages are switchable, a liquid discharge circuit connected to the second port, the first outlet port, the second outlet port, and the collection vessel's port so that flow passages are switchable, a liquid supply mechanism having a switching mechanism, a supply pump, and a discharge pump, and a rotation mechanism rotating the filtering device.

A method for filtering blood is disclosed that in one embodiment includes the steps of depositing unfiltered blood along at least one side of a semi-permeable surface having multiple pores, depositing target tissue along at least an opposing side of the semi-permeable surface, and permitting the unfiltered blood to flow at least partially along the semi-permeable surface to filter the unfiltered blood. Embodiments of the invention can remove self-directed autoantibodies from the blood while reducing the complications of conventional treatments such as plasmaphoresis, and return the patient's own blood cells and its plasma components, less the disease-causing self-directed antibodies. A blood filter and a blood bag are also disclosed.

The present invention concerns an electronic safety system for a RO-device (RO) which is designed to be used with at least one dialysis device (D). The system comprises the RO-device (RO), which is designed for the production of ultrapure water and which is developed with a sensor unit (S) for collecting sensor data and whereby the RO-device (RO) comprises an electronic data interface (RO-S) in order to send the sensor data collected by the sensor unit (5); and it also comprises an analysis unit (AE) which is designed to analyse a water sample with regards to safety requirements and especially with regard to contamination and to generate result data whereby the analysis unit (AE) is also developed with a analysis interface (AE-S) in order to send the generated result data in electronic form; and a network (NW) for the data exchange between the medical-technical entities, especially between the RO-device (RO) and the analysis unit (AE).

A technology that provides various modular biomimetic microfluidic modules emulating varieties of microvasculature in body. These microfluidic-base capillaries and lymphatic Technology modules are constructed as multilayered-microfluidic microchannels of various shapes, and aspect ratios using diverse biocompatible microfluidic polymers. Then, various semipermeable membranes are sandwiched in between these multilayered microfluidic microchannels. These membranes have different chemical, physical characteristics and MWCO values. Consequently, this design will produce much smaller dimension channels similar to human vasculature to achieve biomimetic properties like of human organs and tissues. By interchanging microfluidic-layers or the membranes various diverse modules are designed that act as building blocks for constructing various medical devices, various forms of dialysis devices including albumin and lipid dialysis, water purification, bioreactors, bio-artificial organ support systems. Connecting various modules in diverse combinations, permutations, in parallel and/or in series to ultimately design many unrelated medical devices such as dialysis, bioreactors and organ support devices.